Shares of Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) reached a new 52-week high on Friday . The company traded as high as $30.17 and last traded at $30.41, with a volume of 89513 shares traded. The stock had previously closed at $29.10.
Analysts Set New Price Targets
A number of analysts have recently weighed in on the stock. HC Wainwright raised their price target on shares of Rapt Therapeutics to $27.00 and gave the stock a "buy" rating in a research report on Thursday, July 10th. UBS Group set a $9.00 price target on shares of Rapt Therapeutics and gave the stock a "neutral" rating in a research report on Tuesday, August 12th. Wells Fargo & Company reissued an "overweight" rating and set a $38.00 price target (down previously from $51.00) on shares of Rapt Therapeutics in a research report on Friday, August 8th. Wall Street Zen raised shares of Rapt Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, September 13th. Finally, Leerink Partners raised shares of Rapt Therapeutics from a "market perform" rating to an "outperform" rating and raised their price target for the stock from $16.00 to $37.00 in a research report on Friday, September 26th. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $23.50.
Check Out Our Latest Analysis on Rapt Therapeutics
Rapt Therapeutics Stock Up 3.6%
The company has a 50 day moving average of $14.76 and a 200-day moving average of $10.55. The stock has a market capitalization of $498.52 million, a P/E ratio of -2.13 and a beta of 0.23.
Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.04). Equities analysts forecast that Rapt Therapeutics will post -2.14 EPS for the current fiscal year.
Institutional Investors Weigh In On Rapt Therapeutics
Hedge funds have recently added to or reduced their stakes in the stock. Simplicity Wealth LLC bought a new stake in Rapt Therapeutics in the first quarter valued at $25,000. Invesco Ltd. lifted its stake in Rapt Therapeutics by 411.7% in the first quarter. Invesco Ltd. now owns 58,901 shares of the company's stock valued at $72,000 after buying an additional 47,391 shares during the last quarter. Comerica Bank lifted its stake in Rapt Therapeutics by 53.9% in the first quarter. Comerica Bank now owns 89,327 shares of the company's stock valued at $109,000 after buying an additional 31,287 shares during the last quarter. Callan Family Office LLC lifted its stake in Rapt Therapeutics by 53.9% in the first quarter. Callan Family Office LLC now owns 89,327 shares of the company's stock valued at $109,000 after buying an additional 31,287 shares during the last quarter. Finally, Checkpoint Capital L.P. bought a new stake in shares of Rapt Therapeutics during the first quarter valued at about $134,000. 99.09% of the stock is currently owned by institutional investors.
About Rapt Therapeutics
(
Get Free Report)
RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Rapt Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapt Therapeutics wasn't on the list.
While Rapt Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
